Hayes' Principles and Methods of Toxicology, Sixth Edition

[1]  L. Buckley,et al.  High dose selection in general toxicity studies for drug development: A pharmaceutical industry perspective. , 2009, Regulatory toxicology and pharmacology : RTP.

[2]  G. Sachs,et al.  Gastric H,K-ATPase as therapeutic target. , 1988, Annual review of pharmacology and toxicology.

[3]  D. G. Davey,et al.  The predictive value for man of toxicological tests of drugs in laboratory animals. , 1970, British medical bulletin.

[4]  P. Williams.  The role of pharmacological profiling in safety assessment. , 1990, Regulatory toxicology and pharmacology : RTP.

[5]  E. Hansson,et al.  Toxicology Studies with Omeprazole , 1986 .

[6]  Richard W. Lewis,et al.  Recognition of Adverse and Nonadverse Effects in Toxicity Studies , 2002, Toxicologic pathology.

[7]  J. Contrera,et al.  A Systemic Exposure-Based Alternative to the Maximum Tolerated Dose for Carcinogenicity Studies of Human Therapeutics , 1995 .

[8]  E J Calabrese,et al.  Hormesis as a biological hypothesis. , 1998, Environmental health perspectives.

[9]  James L Stevens,et al.  The future of drug safety testing: expanding the view and narrowing the focus. , 2009, Drug discovery today.

[10]  Samuel M Cohen,et al.  Human carcinogenic risk evaluation: an alternative approach to the two-year rodent bioassay. , 2004, Toxicological sciences : an official journal of the Society of Toxicology.

[11]  B. Butterworth,et al.  Nongenotoxic carcinogens in the regulatory environment. , 1989, Regulatory toxicology and pharmacology : RTP.

[12]  Gary W. Caldwell,et al.  Allometric scaling of pharmacokinetic parameters in drug discovery: Can human CL, Vss and t1/2 be predicted fromin-vivo rat data? , 2004, European Journal of Drug Metabolism and Pharmacokinetics.

[13]  D. Grahame-Smith.  Preclinical toxicological testing and safeguards in clinical trials , 2004, European Journal of Clinical Pharmacology.

[14]  D. Rall,et al.  The evaluation of anticancer drugs in dogs and monkeys for the prediction of qualitative toxicities in man , 1970, Clinical pharmacology and therapeutics.

[15]  C. Schreiner.  APPLICATION OF SHORT‐TERM TESTS TO SAFETY TESTING OF INDUSTRIAL CHEMICALS , 1983, Annals of the New York Academy of Sciences.

[16]  J. French,et al.  The utility of genetically modified mouse assays for identifying human carcinogens: a basic understanding and path forward. The Alternatives to Carcinogenicity Testing Committee ILSI HESI. , 2004, Toxicological sciences : an official journal of the Society of Toxicology.

[17]  K. G. Wormsley.  Omeprazole: Gastrin and gastric data , 1991, Digestive Diseases and Sciences.

[18]  F W Lee,et al.  Testing paradigm for prediction of development-limiting barriers and human drug toxicity. , 2004, Chemico-biological interactions.

[19]  S. Allerheiligen,et al.  Concomitant Toxicokinetics: Techniques for and Interpretation of Exposure Data Obtained During the Conduct of Toxicology Studies , 1995, Toxicologic pathology.

[20]  J. Swenberg.  Bioassay design and MTD setting: old methods and new approaches. , 1995, Regulatory toxicology and pharmacology : RTP.

[21]  G. Hajian,et al.  Nonclinical Toxicology Studies with Zidovudine: Acute, Subacute, and Chronic Toxicity in Rodents, Dogs, and Monkeys , 1996 .

[22]  G. Scott.  Interferon: pharmacokinetics and toxicity. , 1982, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[23]  B. Ames,et al.  Too many rodent carcinogens: mitogenesis increases mutagenesis. , 1990, Science.

[24]  G. Zbinden.  Safety Evaluation of Biotechnology Products , 1990, Drug safety.

[25]  Joy A. Cavagnaro,et al.  Preclinical safety evaluation of biotechnology-derived pharmaceuticals , 2002, Nature Reviews Drug Discovery.

[26]  Nonclinical Toxicology Studies with Zidovudine: Genetic Toxicity Tests and Carcinogenicity Bioassays in Mice and Rats , 1996 .

[27]  T. Priestman,et al.  Monkeys are insensitive to pyrogenic effects of human α-interferons , 1982, Nature.

[28]  J. Contrera,et al.  Carcinogenicity testing and the evaluation of regulatory requirements for pharmaceuticals. , 1997, Regulatory toxicology and pharmacology : RTP.

[29]  Bradley L Ackermann,et al.  Recent advances in use of LC/MS/MS for quantitative high-throughput bioanalytical support of drug discovery. , 2002, Current topics in medicinal chemistry.

[30]  C. E. Lumley.  General pharmacology, the international regulatory environment, and harmonization of guidelines , 1994 .

[31]  R. Tamura,et al.  Comparison of the immunogenicity of recombinant and pituitary human growth hormone in rhesus monkeys. , 1991, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[32]  M. Golub,et al.  Immunological aspects of toxicology: premises not promises. , 1989, Regulatory toxicology and pharmacology : RTP.

[33]  F. Staedtler,et al.  Toxicogenomics in Drug Development , 2003, Toxicologic pathology.

[34]  G. Descotes,et al.  Drug immunotoxicological approaches with some selected medical products: cyclophosphamide, methylprednisolone, betamethasone, cefoxitine, minor tranquillizers. , 1982, Toxicology letters.

[35]  Report of validation study of assessment of direct immunotoxicity in the rat. The ICICIS Group Investigators. International Collaborative Immunotoxicity Study. , 1998, Toxicology.

[36]  E. Calabrese.  Paradigm lost, paradigm found: the re-emergence of hormesis as a fundamental dose response model in the toxicological sciences. , 2005, Environmental pollution.

[37]  J. Haseman.  Issues in Carcinogenicity Testing: Dose Selection , 1985 .

[38]  S. Walker,et al.  The value of chronic animal toxicology studies of pharmaceutical compounds: A retrospective analysis. , 1985, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[39]  J. Dean.  A Brief History of Immunotoxicology and a Review of the Pharmaceutical Guidelines , 2004, International journal of toxicology.

[40]  G. B. Gori.  Are animal tests relevant in cancer risk assessment? A persistent issue becomes uncomfortable. , 1991, Regulatory toxicology and pharmacology : RTP.

[41]  K. Cantell,et al.  Synthesis in E. coli of a polypeptide with human leukocyte interferon activity , 1980, Nature.

[42]  D. Amacher,et al.  A toxicologist's guide to biomarkers of hepatic response , 2002, Human & experimental toxicology.

[43]  D. Hunninghake,et al.  Biotransformation of lovastatin. V. Species differences in in vivo metabolite profiles of mouse, rat, dog, and human. , 1993, Drug metabolism and disposition: the biological fate of chemicals.

[44]  E. Rinderknecht,et al.  Antiviral effects of bacteria-derived human leukocyte interferons against encephalomyocarditis virus infection of squirrel monkeys , 2005, Archives of Virology.

[45]  T. Baillie,et al.  Drug metabolites in safety testing. , 2002, Toxicology and applied pharmacology.

[46]  B. Wallmark.  Mechanism of action of omeprazole. , 1986, Scandinavian journal of gastroenterology. Supplement.

[47]  L. Koller.  A perspective on the progression of immunotoxicology. , 2001, Toxicology.

[48]  A. Riggs,et al.  Expression in Escherichia coli of chemically synthesized genes for human insulin. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[49]  H. Larsson,et al.  Pharmacology and toxicology of omeprazole--with special reference to the effects on the gastric mucosa. , 1986, Scandinavian journal of gastroenterology. Supplement.

[50]  R Scott Obach,et al.  SEEING THROUGH THE MIST: ABUNDANCE VERSUS PERCENTAGE. COMMENTARY ON METABOLITES IN SAFETY TESTING , 2005, Drug Metabolism and Disposition.

[51]  K. Luthman,et al.  Caco-2 monolayers in experimental and theoretical predictions of drug transport , 1996 .

[52]  M. Gralinski.  The assessment of potential for QT interval prolongation with new pharmaceuticals: impact on drug development. , 2000, Journal of pharmacological and toxicological methods.

[53]  Jeffery A Engelhardt,et al.  The no-observed-adverse-effect-level in drug safety evaluations: use, issues, and definition(s). , 2005, Regulatory toxicology and pharmacology : RTP.

[54]  J. Weissinger.  Pharmacology and Toxicology of Novel Drug Delivery Systems , 1990 .

[55]  P. Baldrick.  Pharmaceutical excipient development: the need for preclinical guidance. , 2000, Regulatory toxicology and pharmacology : RTP.

[56]  Munro Ic.  Considerations in chronic toxicity testing: the chemical, the dose, the design. , 1977 .

[57]  Melvin E Andersen,et al.  Toxicokinetics and Physiologically Based Toxicokinetics in Toxicology and Risk Assessment , 2003, Journal of toxicology and environmental health. Part B, Critical reviews.

[58]  D. Davis,et al.  “Hormesis”—An Inappropriate Extrapolation from the Specific to the Universal , 2004, International journal of occupational and environmental health.

[59]  L. Lemberger.  Early clinical evaluation in man: the buck stops here. , 1987, Xenobiotica; the fate of foreign compounds in biological systems.

[60]  Ian Ragan,et al.  Preclinical development of monoclonal antibodies , 2009, mAbs.

[61]  D. Gaylor,et al.  New directions for predicting carcinogenesis , 1997, Molecular carcinogenesis.

[62]  A B Wilson.  The toxicology of the end products from biotechnology processes. , 1987, Archives of toxicology. Supplement. = Archiv fur Toxikologie. Supplement.

[63]  G. Zbinden.  Invited contribution: Acute toxicity testing, public responsibility and scientific challenges , 1986, Cell Biology and Toxicology.

[64]  R. Tennant,et al.  Evaluation of transgenic mouse bioassays for identifying carcinogens and noncarcinogens. , 1996, Mutation research.

[65]  R. W. Hansen,et al.  The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.

[66]  N. Friedmann.  Thymopentin: Safety overview , 1985, Survey of immunologic research.

[67]  J. Caldwell,et al.  The current status of attempts to predict species differences in drug metabolism. , 1981, Drug metabolism reviews.

[68]  C. Bowman,et al.  Preclinical safety evaluations supporting pediatric drug development with biopharmaceuticals: strategy, challenges, current practices. , 2011, Birth defects research. Part B, Developmental and reproductive toxicology.

[69]  M. Klegerman,et al.  Lymphokines and Monokines , 1993 .

[70]  J. Martial,et al.  Human growth hormone: complementary DNA cloning and expression in bacteria. , 1979, Science.

[71]  W. Hoffman,et al.  Analysis of rodent growth data in toxicology studies. , 2002, Toxicological sciences : an official journal of the Society of Toxicology.

[72]  Rick Mullin.  Drug Development Costs About $1.7 Billion , 2003 .

[73]  K. Cassidy,et al.  Characterization of 2-[[4-[[2-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]methyl]quinoline N-glucuronidation by in vitro and in vivo approaches. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[74]  Iftekhar Mahmood,et al.  Interspecies scaling of biliary excreted drugs: a comparison of several methods. , 2005, Journal of pharmaceutical sciences.

[75]  C. E. Lumley,et al.  A Toxicology Databank Based on Animal Safety Evaluation Studies of Pharmaceutical Compounds , 1985, Human toxicology.

[76]  L Ekman,et al.  Toxicological studies on omeprazole. , 1985, Scandinavian journal of gastroenterology. Supplement.

[77]  P. Yi,et al.  A radiocalibration method with pseudo internal standard to estimate circulating metabolite concentrations. , 2010, Bioanalysis.

[78]  Chang-Ho Ahn,et al.  Regulatory considerations for preclinical development of anticancer drugs , 1997, Cancer Chemotherapy and Pharmacology.

[79]  J. Litchfield.  Forecasting drug effects in man from studies in laboratory animals. , 1961, JAMA.

[80]  J. Fenters,et al.  Development of a testing battery to assess chemical-induced immunotoxicity: National toxicology program's guidelines for immunotoxicity evaluation in mice , 1988 .

[81]  P. Trotta.  Preclinical biology of alpha interferons. , 1986, Seminars in oncology.

[82]  J. Zapp.  Extrapolation of animal studies to the human situation. , 1977, Journal of toxicology and environmental health.

[83]  C. Swift,et al.  Stereoselectivity of ibuprofen metabolism and pharmacokinetics following the administration of the racemate to healthy volunteers , 2002, Xenobiotica; the fate of foreign compounds in biological systems.

[84]  P. de Miranda,et al.  Nonclinical toxicology studies with zidovudine: reproductive toxicity studies in rats and rabbits. , 1996, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[85]  M. Fielden,et al.  The role of early in vivo toxicity testing in drug discovery toxicology , 2008 .

[86]  F. Sundler,et al.  Plasma gastrin and gastric enterochromaffinlike cell activation and proliferation. Studies with omeprazole and ranitidine in intact and antrectomized rats. , 1986, Gastroenterology.

[87]  G. Zbinden,et al.  Toxicity of interferon and interleukin , 1987 .

[88]  J. Kramer,et al.  The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates , 2007, Nature Reviews Drug Discovery.

[89]  Kiyomi Ito,et al.  Prediction of Human Drug Clearance from in Vitro and Preclinical Data Using Physiologically Based and Empirical Approaches , 2004, Pharmaceutical Research.

[90]  G. Zbinden.  The significance of pharmacologic screening tests in the preclinical safety evaluation of new drugs. , 1966, The Journal of New Drugs.

[91]  Edward J Calabrese,et al.  Toxicology rethinks its central belief , 2003, Nature.

[92]  Italo Poggesi,et al.  Predicting human pharmacokinetics from preclinical data. , 2004, Current opinion in drug discovery & development.

[93]  Shibing Deng,et al.  A Simple Liquid Chromatography-Tandem Mass Spectrometry Method to Determine Relative Plasma Exposures of Drug Metabolites across Species for Metabolite Safety Assessments , 2010, Drug Metabolism and Disposition.

[94]  K. Norbury.  Immunotoxicology in the pharmaceutical industry. , 1982, Environmental health perspectives.

[95]  Salomon Sand,et al.  The Benchmark Dose Method—Review of Available Models, and Recommendations for Application in Health Risk Assessment , 2003, Critical reviews in toxicology.

[96]  L. Lasagna,et al.  From DNA to NDA--the impact of recombinant DNA technology on new drug development. , 1985, Regulatory toxicology and pharmacology : RTP.

[97]  G. Boorman,et al.  Methods and approaches for assessing immunotoxicity: an overview. , 1982, Environmental health perspectives.

[98]  R. Dunn,et al.  Concise review: gene expression applied to toxicology. , 1999, Toxicological sciences : an official journal of the Society of Toxicology.

[99]  F. Kishida,et al.  Simulation of the toxicokinetics of trichloroethylene, methylene chloride, styrene and n-hexane by a toxicokinetics/toxicodynamics model using experimental data. , 2005, Environmental sciences : an international journal of environmental physiology and toxicology.

[100]  Scott Gm.  The toxic effects of interferon in man. , 1983 .

[101]  J Higginson.  Multiplicity of factors involved in cancer patterns and trends. , 1980, Journal of environmental pathology and toxicology.

[102]  G. Zbinden.  Current trends in safety testing and toxicological research , 1982, Die Naturwissenschaften.

[103]  E J Calabrese,et al.  Improved method for selection of the NOAEL. , 1994, Regulatory toxicology and pharmacology : RTP.

[104]  S. Walker,et al.  An International Appraisal of the Minimum Duration of Chronic Animal Toxicity Studies , 1992, Human & experimental toxicology.

[105]  W M Kluwe.  The complementary roles of in vitro and in vivo tests in genetic toxicology assessment. , 1995, Regulatory toxicology and pharmacology : RTP.

[106]  G. Boorman,et al.  Procedures available to examine the immunotoxicity of chemicals and drugs. , 1982, Pharmacological reviews.

[107]  R. Ings,et al.  New Approaches to the Use of Pharmacokinetics in Toxicology and Drug Development , 1988, Human toxicology.

[108]  B. Lima,et al.  Mechanisms of nongenotoxic carcinogenesis and assessment of the human hazard. , 2000 .

[109]  S. Ankier,et al.  Research and Development of New Medicines , 1989, The Journal of international medical research.

[110]  J Ashby,et al.  Alternatives to the 2-species bioassay for the identification of potential human carcinogens , 1996, Human & experimental toxicology.

[111]  A. Fletcher,et al.  Drug Safety Tests and Subsequent Clinical Experience , 1978, Journal of the Royal Society of Medicine.

[112]  J. Weissinger.  Nonclinical pharmacologic and toxicologic considerations for evaluating biologic products. , 1989, Regulatory toxicology and pharmacology : RTP.

[113]  H. Schellekens,et al.  The Chimpanzee as a Model to Test the Side Effects of Human Interferons , 1984, Journal of medical primatology.

[114]  I. Horii.  Dose selection for carcinogenicity studies of pharmaceuticals. , 1995, The Journal of toxicological sciences.

[115]  L. Lasagna.  PREDICTING HUMAN DRUG SAFETY FROM ANIMAL STUDIES : CURRENT ISSUES , 1987 .

[116]  G. Zbinden.  The problem of the toxicologic examination of drugs in animals and their safety in man , 1964, Clinical pharmacology and therapeutics.

[117]  Anthony Clemento.  New and Integrated Approaches to Successful Accelerated Drug Development , 1999 .

[118]  G. Zbinden.  Effects of recombinant human alpha-interferon in a rodent cardiotoxicity model. , 1990, Toxicology letters.

[119]  R. Pohland,et al.  Comparison of quantitative whole-body autoradiographic and tissue dissection techniques in the evaluation of the tissue distribution of [14C]daptomycin in rats. , 1994, Journal of pharmaceutical sciences.

[120]  V. Bocci.  Physicochemical and biologic properties of interferons and their potential uses in drug delivery systems. , 1992, Critical reviews in therapeutic drug carrier systems.

[121]  D. Jenssen,et al.  Studies of Metabolism Mediated Mutagenicity In Vitro , 1990 .

[122]  R. Frothingham,et al.  Rates of Torsades de Pointes Associated with Ciprofloxacin, Ofloxacin, Levofloxacin, Gatifloxacin, and Moxifloxacin , 2001, Pharmacotherapy.

[123]  Luis G Valerio,et al.  In silico toxicology for the pharmaceutical sciences. , 2009, Toxicology and applied pharmacology.

[124]  Keith W Ward,et al.  A comprehensive analysis of the role of correction factors in the allometric predictivity of clearance from rat, dog, and monkey to humans. , 2004, Journal of pharmaceutical sciences.

[125]  K. Hastings.  Implications of the new FDA/CDER immunotoxicology guidance for drugs. , 2002, International immunopharmacology.

[126]  P. Morrow,et al.  Dust overloading of the lungs: update and appraisal. , 1992, Toxicology and applied pharmacology.

[127]  L. Lasagna.  Clinical testing of products prepared by biotechnology. , 1986, Regulatory toxicology and pharmacology : RTP.

[128]  W. Creutzfeldt,et al.  Session 6: Is Hypergastrinaemia Dangerous to Man? , 1991 .

[129]  Use of the Ames test in toxicology. , 1985, Regulatory toxicology and pharmacology : RTP.

[130]  A. Howell,et al.  A phase I toxicity study of human rDNA interferon in patients with solid tumours , 2004, Cancer Chemotherapy and Pharmacology.

[131]  A. Monro,et al.  What is an appropriate measure of exposure when testing drugs for carcinogenicity in rodents? , 1992, Toxicology and applied pharmacology.

[132]  J. DiMasi.  Risks, regulation, and rewards in new drug development in the United States. , 1994, Regulatory toxicology and pharmacology : RTP.

[133]  J. Bucher,et al.  Evaluating the human relevance of chemically induced animal tumors. , 2004, Toxicological sciences : an official journal of the Society of Toxicology.

[134]  J. Vos,et al.  Histopathologic Approaches to Detect Changes Indicative of Immunotoxicity , 2000, Toxicologic pathology.

[135]  L. Ellwein,et al.  Cell proliferation in carcinogenesis. , 1990, Science.

[136]  J. P. Van Oosterhout,et al.  The utility of two rodent species in carcinogenic risk assessment of pharmaceuticals in Europe. , 1997, Regulatory toxicology and pharmacology : RTP.

[137]  R. Tennant,et al.  Transgenic animals in toxicology. , 1994, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[138]  L Lasagna,et al.  Cost of innovation in the pharmaceutical industry. , 1991, Journal of health economics.

[139]  J. G. Vos,et al.  Immune suppression as related to toxicology. , 1977, CRC critical reviews in toxicology.

[140]  Robert I. Chien.  Issues in pharmaceutical economics , 1979 .

[141]  P. Fu,et al.  Neonatal mouse assay for tumorigenicity: alternative to the chronic rodent bioassay. , 1997, Regulatory toxicology and pharmacology : RTP.

[142]  W. Choy.  Principles of genetic toxicology. , 1996, Drug and chemical toxicology.

[143]  P. Trown,et al.  The preclinical development of roferon®‐A , 1986, Cancer.

[144]  R. Bass,et al.  Toxicological evaluation of biotechnology products: a regulatory viewpoint. , 1987 .

[145]  J. Cavagnaro.  The Principles of ICH S6 and the Case‐by‐Case Approach , 2010 .

[146]  Gary M Williams,et al.  Cellular systems for toxicity testing. , 1983, Annals of the New York Academy of Sciences.